VRPX — Virpax Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Virpax Pharmaceuticals Says Liposomal Formulation Developed To Provide Both Immediate And Sustained Pain Relief
Brief: Virpax Pharmaceuticals On April 2, Got Letter From Nasdaq Stating That Company Was Not In Compliance With Nasdaq Listing Rule
Brief: Virpax Pharmaceuticals Inc On March 15, Got Letter From Nasdaq That Co Has Regained Compliance With Listing Rule 5550(A)(2)
Brief: Virpax Pharmaceuticals Announces Proposed Settlement Of Litigation With Sorrento Therapeutics And Scilex Pharmaceuticals
Brief: Virpax Pharmaceuticals Announces Preliminary Results Of Probudurtm Pilot Study With The U.S. Army Institute Of Surgical Research
Brief: Virpax Pharmaceuticals To Announce The Reverse Stock Split Ratio Between A Range Of 1-To-2 To 1-To-20
Brief: Virpax Pharmaceuticals Announces Leadership Transition
Brief: Virpax Pharmaceuticals Announces That Envelta Remains On Track For Trial In Humans Following FDA Review
Brief: Virpax Pharmaceuticals Announces Extension Of Crada With The U.S. Army Institute Of Surgical Research
Brief: Virpax Pharmaceuticals Says Fot Written Notification From Nasdaq Granting Co's Request For 180-Day Extension To Regain Compliance
Brief: Virpax Pharmaceuticals On Track To Begin First-In-Human Trials Of Probudur In 2024
Brief: Virpax Pharmaceuticals Inc Novvae To Focus Exclusively On Otc Product Candidates
Brief: Virpax Pharmaceuticals Updates On Litigation
Brief: Virpax Pharmaceuticals Files Provisional Patent Application For Intranasal Delivery
Brief: Virpax Pharmaceuticals Enters Into CRADA With The National Advisory Neurological Disorders And Stroke Council
Brief: Virpax Pharmaceuticals Announces CFO Transition
Brief: Virpax Pharmaceuticals Reports 2023 First Quarter Results And Recent Developments
Brief: Virpax Pharmaceuticals Says Remain On Track To File IND For Envelta By Q2 Of 2024
Brief: Virpax Pharmaceuticals Appoints Barbara Ruskin To Its Board